FOR IMMEDIATE RELEASE
- Sponsorship connects Cellgenic to one of Latin America’s largest combined aesthetic, regenerative, and orthomolecular medicine congresses
- Congreso Medéstetica 2026 runs August 19–21 at Salguero Plaza, Buenos Aires, organized by Portal Medestética
- Event combines four concurrent programs, a commercial exhibition, and live procedural demonstrations
MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced its sponsorship of Congreso Internacional Medéstetica 2026 in Buenos Aires, Argentina.
Congreso Medéstetica 2026 runs August 19–21 at Salguero Plaza in Buenos Aires and combines four concurrent programs — the XI International Medical Aesthetics Congress, IV Live Demo Day, the XI Orthomolecular and Integrative Medicine Meeting, and the XIV Cosmiatry and Applied Aesthetics Meeting — alongside a commercial exhibition and live procedural demonstrations, organized by Portal Medestética.
The sponsorship gives Cellgenic direct access to a physician audience spanning aesthetic, regenerative, and orthomolecular medicine, complementing the Company’s existing Argentina commercial operations and reinforcing its regional physician-education and product-visibility strategy.
“Medéstetica brings together exactly the physician disciplines Cellgenic serves — aesthetic, regenerative, and orthomolecular medicine — under one roof,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “This sponsorship is a natural extension of the commercial footprint we’ve been building in Argentina all year.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About Cellgenic
Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), develops and distributes advanced cellular technologies, biologics, peptide therapeutics, and related regenerative-medicine products to physicians and clinics in permitted international markets.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
